A comparison of different intensified upstream processes highlighting the advantage of WuXi Biologics' Ultra‐high Productivity platform (WuXiUP^TM) in improved product quality and purification yield

WuXiUP ^TM , WuXi Biologics’ Ultra‐high Productivity platform, is an intensified and integrated continuous bioprocess platform developed for production of various biologics including monoclonal antibodies, fusion proteins, and bispecific antibodies. This process technology platform has manifested its remarkable capability in boosting the volumetric productivity of various biologics and has been implemented for large‐scale clinical material productions. In this paper, case studies of the production of different pharmaceutical proteins using two high‐producing and intensified culture modes of WuXiUP ^TM and the concentrated fed‐batch (CFB), as well as the traditional fed‐batch (TFB) are discussed from the perspectives of cell growth, productivity, and protein quality. Both WuXiUP ^TM and CFB outperformed TFB regarding volumetric productivity. Additionally, distinctive advantages in product quality profiles in the WuXiUP ^TM process, such as reduced acidic charge variants and fragmentation, are revealed. Therefore, a simplified downstream purification process with only two chromatographic steps can be developed to deliver the target product at a satisfactory purity and an extremely‐high yield.